Relationship Between CHADS-VASc Score on Admission and In-Hospital Major Adverse Cardiovascular Events in Patients

Duygu Inan1, Duygu Genc1, Barış Şimsek2

  • 1Department of Cardiology, Basaksehir Cam & Sakura City Hospital, Istanbul, Turkey.

Angiology
|August 12, 2024
PubMed

Insights

The CHA₂DS₂-VASc score predicts major adverse cardiovascular events (MACE) in ST-elevation myocardial infarction (STEMI) patients without atrial fibrillation. This score, along with other factors, helps estimate in-hospital risks.

Area of Science:

  • Cardiology
  • Clinical Risk Prediction

Background:

  • The CHA₂DS₂-VASc score is established for thromboembolism risk in atrial fibrillation.
  • Its utility in ST-elevation myocardial infarction (STEMI) patients without atrial fibrillation is less understood.

Purpose of the Study:

  • To evaluate the CHA₂DS₂-VASc score's effectiveness in predicting major adverse cardiovascular events (MACE) in STEMI patients.
  • To identify independent predictors of MACE in this population.

Main Methods:

  • Retrospective analysis of STEMI patients without atrial fibrillation.
  • Assessed CHA₂DS₂-VASc score as a predictor of MACE (in-hospital death or cerebrovascular accident).
  • Utilized multivariable analysis and developed a risk nomogram.

Main Results:

  • MACE occurred in 10% of patients.
  • CHA₂DS₂-VASc score was an independent predictor of MACE (95% CI, 2.31 [1.37-3.9]; P = .0016).
  • Other predictors included heart rate, Killip class, creatinine, CK-MB, and no-reflow.

Conclusions:

  • The CHA₂DS₂-VASc score is a valuable tool for predicting MACE in STEMI patients lacking atrial fibrillation.
  • The study highlights the score's applicability beyond its original indication.
  • A nomogram aids in estimating in-hospital adverse outcomes for STEMI patients.